Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: A pilot study

Clinical and Experimental Obstetrics and Gynecology

Volumn 38, Issue 3, 2011, Pages 232-235

  Margarido, P F R ^a   Bagnoli, V R ^a   Maggio Da Fonseca, A ^a   Maciel, G A R ^a   Soares Jr , J M ^a   D'Amico, E A ^a   Baracat, E C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blood coagulation; Fibrinogen; Hormone therapy; Menopause; Venous thromboembolism

Indexed keywords

ESTRADIOL; FIBRINOGEN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HUMAN; MENOPAUSE; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; ADULT; ANALYSIS OF VARIANCE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBRINOGEN; HUMANS; MIDDLE AGED; PILOT PROJECTS; THROMBELASTOGRAPHY; VENOUS THROMBOEMBOLISM;

EID: 80054092936     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Writing Group for the PEPI Trial: "Effects of hormone replacement therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial". JAMA, 1996, 276, 1389.
2. Rossouw J.E.: "Coronary heart disease in menopausal women: Implications of primary and secondary prevention trials of hormones". Maturitas, 2005, 51, 51.
3. Writing Group for the Women's Health Initiative Investigators: "Principal results from the women's health initiative randomized controlled trial". JAMA, 2002, 288, 321.
4. Lowe G.D.O.: "Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease". J. Int. Med., 2004, 256, 361.
5. Wu O.: "Postmenopausal hormone replacement therapy and venous thromboembolism". Gender Med., 2005, 2 (suppl. 1), S18.
6. Lip G.Y., Blann A.D., Jones A.F., Beevers D.G.: "Effects of hormone-replacement therapy on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis". Am. Heart J., 1997, 134, 764.
7. Gomes M.P.V., Deitcher S.R.: "Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review". Arch. Intern. Med., 2004, 164, 1965.
8. Speroff L., Gilbert R.D., Ellman H. for the estradiol acetate Investigator Group: "Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms". Menopause, 2006, 13, 442.
9. Modena M.G., Sismondi P., Mueck A.O., Kuttenn F., Lignières, B., Verhaeghe J. et al.: "New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits". Maturitas, 2005, 52, 1.
10. Bertina R.M.: "Elevated clotting factor levels and venous thrombosis". Pathophysiol haemost. thromb., 2004, 33, 395.
11. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M.: "A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis". Blood, 1996, 88, 3698.
12. Schreiber M.A., Differding J., Thorborg P., Mayberry J.C., Mullins R.J.: "Hypercoagulability is most prevalent early after injury and in female patients". J. Trauma, 2005, 58, 475.
13. Han K.K., Soares J.M. Jr, Haidar M.A., de Lima G.R., Baracat E.C.: "Benefits of soy isoflavone therapeutic regimen on menopausal symptoms". Obstet. Gynecol., 2002, 99, 389.
14. Sztejnsznajd C., Silva M.E., Nussbacher A., Gebara O.E., D'AmicoE.A., Rocha D.M. et al.: "Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus". Metabolism, 2006, 55, 953.
15. Quick A.J., Stanley-Brown M., Bancroff F.W.: "A study of the coagulation defect in hemophilia and jaundice". Am. J. Med. Science, 1935, 190, 501.
16. Ingram G.F., Matchett M.O.: "The serial thrombin time method for measuring fibrinogenolytic activity in plasma". Nature, 1960, 188, 674.
17. Bell W.N., Alton H.C.: "A brain extract as a substitute for platelet suspension in the thromboplastin generation test". Nature, 1954, 174, 880.
18. Brecher G., Cronkite E.P.: "Morphology and enumeration of human blood platelets". J. Appl. Physiol., 1950, 3, 365.
19. Clauss A.: "Rapid physiological coagulation method for the determination of fibrinogen". Acta Haemal., 1957, 17, 237.
20. NIH State-of-the-Science Panel: "National Institutes of Health State-of-the-Science Conference Statements: Management of menopause-Related Symptoms". Ann. Intern. Med., 2005, 142, 1003.
21. Rosendaal F.R.: "Venous thrombosis: a multicausal disease". Lancet, 1999, 353, 1167.
22. rd: "The epidemiology of venous thromboembolism in the community". Thromb. Haemost., 2001, 86, 452.
23. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M.: "Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens". Lancet, 1996, 348, 981.
24. Varas-Lorenzo C., García-Rodríguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., Perez-Gutthann S.: "Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe". Am. J. Epidemiol., 1998, 147, 387.
25. Task Force on Pulmonary Embolism, European Society of Cardiology: "Guidelines on diagnosis and management of acute pulmonary embolism" Eur. Heart J., 2000, 21, 1301.
26. Seligsohn U., Lubetsky A.: "Genetic susceptibility to venous thrombosis". N. Engl. J. Med., 2001, 344, 1222.
27. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., Vandenbroucke J.P.: "Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms-the Leiden Thrombophilia Study (LETS)". Thromb. Haemost., 1994, 71, 719.
28. Lowe G.D., Rumley A., Woodward M., Morrison C.E., Philippou H., Lane D.A., Tunstall-Pedoe H.: "Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use". Br. J. Haematol., 1997, 97, 775.
29. Zegura B., Keber I., Sebestjen M., Koenig W.: "Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis". Atherosclerosis, 2003, 168, 123.
30. Taner M.Z., Ozpolat E., Taskiran C., Onan M.A., Gursel T., Karabulut E. et al.: "Effects of four different regimens of hormone replacement therapy on hemostatic parameters: A prospective randomized study". Maturitas, 2006, 53, 267.
31. Lindoff C., Peterson F., Lecander I., Martinsson G., Astedt B.: "Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease". Maturitas, 1996, 24, 43.
32. Zegura B., Guzic-Salobir B., Sebestjen M., Keber I.: "The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women". Menopause, 2006, 3, 643.